Oxford Biomedica (OXB)

Sector:

Pharma and Biotech

Index:

FTSE Small Cap

NULL
   
  • Closing Price Chg:
      18.00p
  • 52 Week High: NULL
  • 52 Week Low: 233.00p
  • Currency: UK Pounds
  • Shares Issued: 106.14m
  • Volume: 0
  • RiskGrade: 125
  • Beta: 0.02

OXB Overview

Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.
Registrars: Capita Registrars

Key Personnel

CEO: Frank Mathias
CFO: Lucinda (Lucy) Crabtree
Chairman: Roch Doliveux
Independent Non-Executive Director: Namrata P Patel
Independent Non-Executive Director: Heather Preston
Senior Independent Director: Dame Kay Davies
Non-Executive Dir: Robert Ghenchev, Laurence Espinasse, Colin Bond , Peter Soelkner

Contact Details

Address: Windrush Court, Transport Way, Oxford, United Kingdom, OX4 6LT
Phone: +44 (0) 1865 783 000
Fax: +44 (0) 1865 783 001
Website: http://www.oxb.com/

Listings

Sector: Pharma and Biotech(LSE)
Index: techMARK, FTSE Small Cap, FTSE All-Share, FTSE techMARK Focus
Overseas Listings: BATSLON:OXBL
ISIN: GB00BDFBVT43

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

OXB Market Data

Currency UK Pounds
Share Price NULL
Closing Price Change 18.00p
% Change 0.00 %
52 Week High NULL
52 Week Low 233.00p
Volume 0
Shares Issued 106.14m
Beta 0.02
RiskGrade 125

OXB Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
32.44% below the market average32.44% below the market average32.44% below the market average32.44% below the market average32.44% below the market average
31.71% above the sector average31.71% above the sector average31.71% above the sector average31.71% above the sector average31.71% above the sector average
Price Trend
53.87% above the market average53.87% above the market average53.87% above the market average53.87% above the market average53.87% above the market average
77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average77.78% above the sector average
Income Not Available
Growth
4.65% above the market average4.65% above the market average4.65% above the market average4.65% above the market average4.65% above the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average

What The Brokers Say

Strong Buy 4
Buy 2
Neutral 4
Sell 0
Strong Sell 0
Total 10
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

OXB Dividends

No dividends found

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

OXB Key Personnel

Chair Roch Doliveux
CEO Frank Mathias
CFO Lucinda (Lucy) Crabtree

Top of Page